重度未控制哮喘患者特征、生物标志物与急性加重风险
该研究汇总7项生物制剂随机对照试验的安慰剂组数据,共2016例重度未控制哮喘患者。结果显示,既往频繁或严重急性加重、鼻息肉、维持口服激素、亚洲种族及地区、血嗜酸性粒细胞和呼出气一氧化氮升高与年化急性加重率升高相关。
要点
- 既往12个月内频繁或严重急性加重是急性加重风险升高的重要临床特征。
- 血嗜酸性粒细胞≥300 cells·μL-1且FENO≥50 ppb时年化急性加重率最高。
- 联合血嗜酸性粒细胞和FENO的2型炎症标准比单一生物标志物预后价值更高。
核心结论
- 急性加重史、维持口服激素、鼻息肉、亚洲种族、地理区域以及血嗜酸性粒细胞和FENO升高与重度未控制哮喘急性加重风险增加相关。
研究设计与样本
- 汇总7项设计相似、纳入相似人群的生物制剂治疗重度未控制哮喘的II期和III期随机对照试验的安慰剂组数据,共2016例患者。
主要发现
- 安慰剂组合并年化急性加重率为0.91(95% CI 0.84‒0.98)。
- 基线血嗜酸性粒细胞计数和FENO浓度升高与年化急性加重率增加相关,血嗜酸性粒细胞≥300 cells·μL-1且FENO≥50 ppb时年化急性加重率最高。
- 基线血清IgE浓度与年化急性加重率无关系。
- 联合血嗜酸性粒细胞和FENO的2型炎症标准比任一生物标志物单独具有更高的预后价值。
- 研究期间持续血嗜酸性粒细胞和FENO升高与更高的年化急性加重率相关。
关键数值与推荐
- 年化急性加重率按基线临床特征及基线和研究期间生物标志物浓度评估。
- 与年化急性加重率升高相关的基线特征包括:既往12个月内频繁或严重急性加重、鼻息肉、维持口服激素使用、亚洲种族及亚洲或西欧地区。
临床怎么用
- 对重度未控制哮喘患者,应评估既往急性加重史、维持口服激素使用、鼻息肉、种族和地理区域等临床特征以识别高风险者。
- 可检测基线血嗜酸性粒细胞计数和FENO浓度,尤其关注两者同时升高或持续达到2型炎症标准者,以辅助风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Greater precision in asthma exacerbation risk prediction may improve outcomes. We sought to identify clinical characteristics and biomarkers associated with elevated exacerbation risk in patients with severe, uncontrolled asthma. METHODS: Data were pooled from seven similarly designed phase II and III randomised controlled clinical trials of biologic therapies for the treatment of severe, uncontrolled asthma that enrolled comparable patient populations. Annualised asthma exacerbation rates (AAERs) for patients randomised to placebo were assessed by baseline clinical characteristics, and by biomarker concentrations at baseline and over the study duration. RESULTS: The AAER for the 2016 patients in the combined placebo group was 0.91 (95% CI 0.84‒0.98). Baseline characteristics associated with greater AAER were frequent or severe exacerbations within the prior 12 months, nasal polyposis, maintenance oral corticosteroid use, Asian race and Asian or Western European region. AAER increased with baseline blood eosinophil counts and exhaled nitric oxide fraction (F ENO) concentration, with the greatest AAER occurring for patients with eosinophils ≥300 cells·μL-1 and F ENO ≥50 ppb. No relationship was observed between baseline serum IgE concentration and AAER. Combining type 2 inflammation criteria for eosinophils and F ENO had greater prognostic value than either biomarker alone. Persistent eosinophil and F ENO elevations throughout the study period were associated with greater AAER. CONCLUSIONS: Exacerbation history, maintenance corticosteroid use, nasal polyposis, Asian race, geographic region, and elevations in blood eosinophil counts and F ENO concentrations (particularly when combined and/or persistently achieving type 2 inflammation criteria) were associated with increased exacerbation risk in patients with severe, uncontrolled asthma.
引用
- Kraft M, Brusselle G, FitzGerald JM, et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. Eur Respir J. 2021. PMID: 34112734. doi:10.1183/13993003.00413-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。